Protocol Ledger

NCT04345523 · Phase II · COMPLETED

Convalescent Plasma Therapy vs. SOC for the Treatment of COVID-19 in Hospitalized Patients

Interventional Phase II clinical trial protocol NCT04345523 sponsored by Cristina Avendaño Solá in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-04-03 Enrollment: 350 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04345523
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)350 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04345523
Protocol FieldVerified Registry Value
NCT IdentifierNCT04345523
Consolidated Lead SponsorCristina Avendaño Solá
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment350 participants (ACTUAL)
Registered Start Date2020-04-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04345523
Hospital Research SiteLocationSite Profile
Hospital Universitario Puerta de Hierro MajadahondaMajadahonda, SpainOpen Hospital Dossier ->
Hospital del MarBarcelona, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI